Skip to main content
SpringerLink
Log in

12-month efficacy and safety of OROS® MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH

  • ORIGINAL CONTRIBUTION
  • Published:
European Child & Adolescent Psychiatry Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to evaluate long-term clinical treatment with OROS® methylphenidate (MPH) (Concerta®) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had been previously treated with immediate release (IR) MPH.

Methods

Subjects aged 6–16 years (n=105) who were stable on IR MPH (10–60 mg/day) were switched to 18, 36 or 54mg OROS® MPH once daily for 21 days, depending on prestudy MPH dose. Subjects who benefited from OROS® MPH could continue in a 12-month extension period. ADHD symptoms and treatment response were assessed by parents/caregivers and investigators.

Results

Out of 105 enrolled children, 101 completed the 21-day treatment phase. In all, 89 parents/caregivers (88.1%) wanted their child to continue with the study treatment into the extension phase, and 56 children (63 %) completed the 1-year trial. The parent/caregiver global assessment of satisfaction ranged from 49 to 69% during the extension phase, and 49 to 71% of investigators rated the treatment as adequate. Efficacy and satisfaction were found more commonly in patients in the older age group (10–16 years), those on a higher dose (36 mg or 54 mg) and with the predominantly inattentive ADHD subtype. OROS® MPH was well tolerated.

Conclusions

Children and adolescents can effectively and safely be switched from IR MPH to OROS® MPH with improved symptom control and compliance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Academy of Child and Adolescent Psychiatry (1997) Practice parameter for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactive disorder. J Am Acad Child Adolesc Psychiatry 36 (Suppl): 85S–121S www.aacap.org/clinical/Adhdsum.htm.Accessed 10 May 2004

    PubMed  Google Scholar 

  2. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S; American Academy of Child and Adolescent Psychiatry (2002) Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41(2 Suppl):26S–49S

    PubMed  Google Scholar 

  3. Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, Findling RL, Fisman S, Greenhill LL, Huss M, Kusumakar V, Pine D, Taylor E, Tyano S (2004) International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 14:11–28

    Article  PubMed  Google Scholar 

  4. Loney J, Milich R (1982) Hyperactivity, inattention, and aggression in clinical practice. In: Wolraich M, Routh DK (eds) Advances in Development and Behavioral Pediatrics. JAI Press. Greenwich, CT, pp 113–147

  5. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M (1993) Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 50:565–576

    PubMed  Google Scholar 

  6. National Institute for Clinical Excellence (2002) Technology Appraisal Guidance-No 13. Guidance on the use of methylphenidate (Ritalin, Equasym) for attention-deficit/hyperactivity disorder (ADHD) in childhood. October. www.nice.org.uk/article.asp?a = 11667. Accessed 10 May 2004

  7. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN,Morse GD (2001) Once- a-day Concerta methylphenidate versus threetimes-daily methylphenidate in laboratory and natural settings. Pediatrics 107:E105

    Article  PubMed  Google Scholar 

  8. Remschmidt H, Hoare P, Ettrich C, Rothenberger A, Santosh P, Schmit M, Spender Q, Tamhne R, Thompson M, Tinline C, Trott GE, Medori R (in press) Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH: results of a 3-week open-label study. Eur Child Adolesc Psychiatry

  9. Stein MA, Greenhill LL (2002) Oncedaily Concerta (MPH) for adolescents and adults with ADHD. Int J Neuropsychopharmacol 5(Suppl 1):S162

    Google Scholar 

  10. Wilens TE (2002) Treatment of ADHD with once-daily OROS methylphenidate: results from a long-term openlabel study. Presented at 155th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 18–22

  11. Wilens TE (personal communication) A multisite, controlled trial of OROS® methylphenidate (CONCERTA®) in the treatment of adolescents with attention-deficit/hyperactivity disorder

  12. Wilens T, Pelham W, Stein MA,Conners CK, Abikoff H, Atkins M, August G, Greenhill L, McBurnett K, Palumbo D, Swanson J, Wolraich M (2003) ADHD treatment with once-daily OROS® methylphenidate: interim 12-month results from long-term open-label study. J Am Acad Child Adolesc Psychiatry 42:424–433

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Child and Family Mental Health Service, Royal Hospital for Sick Children, 3 Rillbank Terrace, Edinburgh EH9 1LL, UK

    Peter Hoare

  2. Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters, Hans-Sachs-Strasse 6, 35033, Marburg, Germany

    H. Remschmidt

  3. Janssen-Cilag Europe, Middle-East, Africa, Raiffeisenstraße 8, 41470, Neuss, Germany

    R. Medori

  4. Kinder- und Jugendpsychiatrie der Universität Leipzig, Dritte Etage, Riemannstrasse 32–34, 04107, Leipzig, Germany

    C. Ettrich

  5. Kinder und Jugendpsychiatrie der Georg-August Universität, Von-Siebold-Strasse 5, 37075, Göttingen, Germany

    A. Rothenberger

  6. Maudsley Hospital, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK

    P. Santosh

  7. Kinder- und Jugendpsychiatrie Klinik Zentralinstitut für seelische Gesundheit, 122120, 68159, Mannheim, Germany

    M. Schmit

  8. Orchard House Sussex Weald and Downs NHS Trust, 9 College Lane, Chichester PO19 4PQ, UK

    Q. Spender

  9. Leicestershire and Rutland Healthcare Trust, Bridge Park Plaza, Thurmaston, Leicester LE4 8PQ, UK

    R. Tamhne

  10. Ashurst Hospital, Department of Psychiatry, Lyndhurst, Southampton SO40 7AR, UK

    M. Thompson

  11. The Pear Tree Centre Child and Family Therapy Service, Smallwood House, Church Green West, Redditch, Worcestershire B97 4BD, UK

    C. Tinline

  12. Privatpraxis, Frohsinnstrasse 26, 63739, Aschaffenburg, Germany

    G. E. Trott

Authors
  1. Peter Hoare
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Remschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Medori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Ettrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Rothenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Santosh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Schmit
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Q. Spender
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R. Tamhne
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C. Tinline
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. G. E. Trott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Hoare.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoare, P., Remschmidt, H., Medori, R. et al. 12-month efficacy and safety of OROS® MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Europ.Child & Adolescent Psych 14, 305–309 (2005). https://doi.org/10.1007/s00787-005-0486-3

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00787-005-0486-3

Key words

Search

Navigation